Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

HC Wainwright restated their buy rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $81.00 price ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein ...

Also Read: Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial The trial also showed an encouraging safety/tolerability profile and favorable ...

Truist analyst Joon Lee lowered the firm’s price target on Arvinas (ARVN) to $21 from $65 and keeps a Buy rating on the shares as part of a ...

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced ...